export default function PegMgfOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        PEG-MGF is a synthetic version of a naturally occurring muscle repair signal your body already produces in response to hard training &mdash; with a chemical modification intended to make it last longer in circulation. The biology is real and interesting. The problem: there is zero human clinical trial data, you can&rsquo;t verify what you&rsquo;re actually injecting from gray-market sources, and the growth factor pathway it activates has documented links to tumor growth. Progressive overload already maximizes your natural version of this signal without any of those risks.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Injury Recovery Person &mdash; slow to heal, looking for an edge</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I tore something and it&rsquo;s taking forever to heal &mdash; is there a peptide that actually helps muscle regenerate faster?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The mechanism sounds exactly right for injury</strong><br />MGF is produced locally in damaged muscle and activates satellite cells &mdash; the stem cells that actually rebuild muscle fibers after injury. For someone with a frustrating slow-healing muscle tear, a compound targeting this specific repair mechanism sounds ideal.</li>
          <li><strong>The community talks about it for injury protocols</strong><br />PEG-MGF appears in the same communities that discuss BPC-157 and TB-500 for injury, often recommended as a muscle-specific addition to those more commonly used compounds. The anecdotes are plentiful even if the evidence isn&rsquo;t.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">All the evidence is from rodent studies &mdash; there is no human data at any level. Whether injecting a gray-market compound into or near a healing muscle injury actually reaches the satellite cells you care about, at concentrations that do anything, is completely unknown. The product you&rsquo;re buying has no verified identity guarantee. And for someone dealing with an injury, adding an uncharacterized growth factor compound introduces cancer-risk concerns that are particularly bad timing. Net: biologically plausible story, no human evidence, meaningful uncharacterized risks &mdash; not the right call for injury recovery.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; muscle repair, post-workout recovery, satellite cell activation</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;Could this actually increase muscle satellite cell activation beyond what training already does, and is the PEGylation doing anything useful?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The satellite cell story is compelling for advanced athletes</strong><br />Satellite cell activation is the rate-limiting step in muscle fiber repair and growth after damage. If you could reliably amplify that signal above what training already produces, the recovery advantage would be real. Heavy training maximizes endogenous MGF, but the idea of pushing further is attractive to someone already optimized on the training side.</li>
          <li><strong>PEGylation extends half-life for systemic delivery</strong><br />The natural MGF peptide is short-lived and acts locally near the site of muscle damage. The PEGylation modification allows systemic injection with slower clearance &mdash; theoretically distributing the signal to all trained muscles rather than requiring local injection into each.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The most important comparison is against your own training response: progressive overload already maximizes endogenous MGF expression in exercised muscle. Whether exogenous PEG-MGF adds anything meaningful on top of that, in a well-trained athlete whose satellite cells are already responding normally, is not tested. Whether subcutaneous injection actually reaches muscle tissue at relevant concentrations is unknown. The IGF-1 pathway concern is real: growth factor axis dysregulation has established oncogenesis links, and an uncharacterized compound in that axis adds genuinely unquantifiable risk. Net: theoretically interesting, practically uncharacterized, real risk profile that outweighs speculative benefit.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; IGF-1 splice variant biology, satellite cell signaling</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;What&rsquo;s the actual evidence that MGF acts through a distinct pathway from IGF-1R? Is the E-domain peptide doing something different, or is this just IGF-1 biology with extra steps?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The proposed mechanism is genuinely distinct from IGF-1</strong><br />MGF is derived from the E domain of the IGF-1Ec splice variant &mdash; a region not present in mature IGF-1. Early research proposed that the E domain peptide acts through a receptor distinct from IGF-1R, specifically activating satellite cells following mechanical damage rather than driving systemic growth. Whether this distinction is real at the receptor level, and whether it matters pharmacologically, is unresolved but scientifically interesting.</li>
          <li><strong>PEGylation is a legitimate pharmaceutical strategy</strong><br />PEGylation of peptides to extend half-life is a well-established approach used in approved biologics. The application to MGF for systemic injection is a rational extension of that strategy. The pharmacological engineering question of whether PEGylated MGF distributes to muscle and maintains activity is worth understanding even if the answer isn&rsquo;t established.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The &ldquo;distinct MGF receptor&rdquo; hypothesis remains unconfirmed at the molecular level. Gray-market PEG-MGF has no synthesis verification &mdash; D-amino acid composition, PEGylation quality, and concentration are all unknown without rigorous third-party testing. PEG accumulation with repeated dosing is a theoretical concern that is also uncharacterized for this compound specifically. The cancer concern is not paranoia: IGF-1 pathway activation is mechanistically linked to tumor growth across multiple cancer types, and any compound in this axis without human safety data carries that concern. Net: fascinating biology, genuinely unresolved science, risk profile that makes this one to watch from the sidelines rather than experiment with personally.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What PEG-MGF is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>A compound with any human clinical evidence &mdash; all data is from animal models</li>
              <li>A verified product when purchased from gray-market suppliers &mdash; identity, purity, and concentration are unknown</li>
              <li>A safe addition to an anabolic stack &mdash; combination safety is completely uncharacterized</li>
              <li>A free pass on cancer risk &mdash; IGF-1 pathway activation has established oncogenesis links</li>
              <li>Something that adds to what heavy progressive overload already does endogenously &mdash; training already maximizes the natural signal</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>Satellite cell activation is a real and important muscle repair mechanism &mdash; the biological target is legitimate</li>
              <li>The proposed distinct MGF E-domain mechanism vs. IGF-1R is a genuinely unresolved and interesting scientific question</li>
              <li>PEGylation for systemic delivery of a naturally local signal is a rational pharmacological engineering idea</li>
              <li>Active rodent research provides mechanistic detail even if human translation is absent</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
